The rise of degrader drugs
Mingxing Teng1, Nathanael S Gray2
1Center for Drug Discovery, Department of Pathology & Immunology, and Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Abstract:
The cancer genomics revolution has served up a plethora of promising and challenging targets for the drug discovery community. The field of targeted protein degradation (TPD) uses small molecules to reprogram the protein homeostasis system to destroy desired target proteins. In the last decade, remarkable progress has enabled the rational development of degraders for a large number of target proteins, with over 20 molecules targeting more than 12 proteins entering clinical development. While TPD has been fully credentialed by the prior development of immunomodulatory drug (IMiD) class for the treatment of multiple myeloma, the field is poised for a "Gleevec moment" in which robust clinical efficacy of a rationally developed novel degrader against a preselected target is firmly established. Here, we endeavor to provide a high-level evaluation of exciting developments in the field and comment on steps that may realize the full potential of this new therapeutic modality.
Insights
Targeted protein degradation (TPD) offers a novel therapeutic approach by using small molecules to eliminate disease-causing proteins. This field is rapidly advancing, with numerous TPD drugs entering clinical trials for various cancers.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Cancer genomics has identified numerous therapeutic targets.
- Targeted protein degradation (TPD) is an emerging modality that hijacks cellular machinery to degrade proteins.
- Over 20 TPD molecules targeting more than 12 proteins are in clinical development.
Purpose of the Study:
- To provide a high-level evaluation of recent advancements in targeted protein degradation.
- To discuss strategies for realizing the full therapeutic potential of TPD.
- To highlight the potential for a "Gleevec moment" in TPD drug development.
Main Methods:
- Review of current literature and clinical trial data in targeted protein degradation.
- Analysis of the progress and challenges in developing novel protein degraders.
- Evaluation of the clinical validation of TPD based on existing drug classes like IMiDs.
Main Results:
- Significant progress in the rational design and development of TPD molecules.
- Successful clinical entry of numerous TPD candidates.
- Established precedent for TPD through immunomodulatory drugs (IMiDs) in multiple myeloma.
Conclusions:
- The field of targeted protein degradation is rapidly maturing.
- TPD holds significant promise as a new therapeutic modality for cancer treatment.
- Further development and clinical validation are crucial to establish TPD's full potential.
More Related Videos
10:17High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Related Concept Videos
Drugs that Destabilize Microtubules
Desensitization and Tachyphylaxis
Prodrugs
Prodrugs help overcome...
Drug Biotransformation: Overview
Depressants
Alcohol is a common depressant that can induce a sense of relaxation and reduced inhibition at low doses. Contrary to its occasional...
Enhanced Elimination of Poison
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
